Patient heterogeneity in phase II studies of refractory disease in multiple myeloma--the 'spell' of the time to first relapse.
Hermansen
N Emil U
NE
Gimsing
Peter
P
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002908:Chronic Disease; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000401:mortality*; D012008:Recurrence; D016019:Survival Analysis
D000970:Antineoplastic Agents